Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | TERT | O14746 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663647 | 0.85 | CA2 (0.58) | POLBCYP1A2CYP2C9CA12CA2 | |
| SCHEMBL4400398 | 0.84 | L3MBTL1 (0.71) | CYP1A2CYP2C9ALDH1A1L3MBTL1LTA4H | |
| SCHEMBL18602214 | 0.84 | MAPT (0.68) | POLBTERTALDH1A1MEN1KMT2A | |
| SCHEMBL11031322 | 0.83 | CYP1A2 (0.67) | CYP1A2CYP2C9ALDH1A1L3MBTL1LTA4H | |
| SCHEMBL7824720 | 0.83 | CYP1A1 (0.70) | POLBCYP1A2CYP2C9CA12CA2 | |
| Hydrochloric Acid SCHEMBL12477633 | 0.82 | L3MBTL1 (0.69) | CYP1A2CYP2C9ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL265614 | 0.81 | TP53 (0.70) | POLBCYP1A2CYP2C9CA12CA2 | |
| SCHEMBL11520695 | 0.81 | CA2 (0.58) | POLBCYP1A2CYP2C9CA12CA2 | |
| SCHEMBL4683731 | 0.81 | CYP1A2 (0.56) | POLBCYP1A2CYP2C9CA12CA2 | |
| SCHEMBL28010779 | 0.81 | POLB (0.57) | POLBCYP1A2CYP2C9CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1294722-B1 | METHODS OF SYNTHESIS FOR 9-SUBSTITUTED HYPOXANTHINE DERIVATIVES | MERCK EPROVA AG (CH) | 2007-08-01 | — | — | EP | claimed |
| EP-2956437-B1 | ALBICIDIN DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | UNIV BERLIN TECH (DE) | 2023-05-10 | — | — | EP | disclosed |
| US-10308595-B2 | Albicidin derivatives, their use and synthesis | Technische Universität Berlin (DE) | 2019-06-04 | — | — | US | disclosed |
| US-20150376120-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | Technische Universität Berlin (DE) | 2015-12-31 | — | — | US | disclosed |
| US-20150376120-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | Technische Universität Berlin (DE) | 2015-12-31 | — | — | US | disclosed |
| WO-2014125075-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | Technische Universität Berlin (DE) | 2014-08-21 | — | — | WO | disclosed |
| EP-1294722-B1 | METHODS OF SYNTHESIS FOR 9-SUBSTITUTED HYPOXANTHINE DERIVATIVES | MERCK EPROVA AG (CH) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308595-B2 | Albicidin derivatives, their use and synthesis | MB, ALB, BCAT2 | POLB 305/4885CYP1A2 1530/4885CYP2C9 803/4885 |
| US-20150376120-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | MB, ALB, BCAT2 | POLB 305/4885CYP1A2 1530/4885CYP2C9 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.